Biolase (Biolase) Interest Expense : $-2.41 Mil (TTM As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Biolase Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biolase's interest expense for the three months ended in Mar. 2024 was $ -0.62 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.41 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biolase's Operating Income for the three months ended in Mar. 2024 was $ -4.53 Mil. Biolase's Interest Expense for the three months ended in Mar. 2024 was $ -0.62 Mil. Biolase did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biolase Interest Expense Historical Data

The historical data trend for Biolase's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Interest Expense Chart

Biolase Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.16

-2.36

-2.22

-2.75

-2.36

Biolase Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.58	-0.58	-0.60	-0.60	-0.62

Biolase Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.41 Mil.

Biolase (NAS:BIOL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biolase's Interest Expense for the three months ended in Mar. 2024 was $-0.62 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-4.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $11.75 Mil.

Biolase's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Biolase did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Biolase (Biolase) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BTH0:Germany

Address

27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610

Website

https://www.biolase.com

Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Executives

Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md	director	500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright	officer: Chief Financial Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor	officer: Chief Operating Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver	director, officer: President & CEO	C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg	10 percent owner	C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla	director	3299 CAMBRIDGE AVE, BRONX NY 10463